Our firm is looking at cases involving a product known as oral sodium phosphate. OSP is a laxative that is commonly given to patients to cleanse the bowels prior to procedures, such as colonoscopies, endoscopic and radiologic examinations, and surgeries. The primary product being used is Fleet® Phospho-Soda®, which is manufactured by C.B. Fleet Company, Inc., and which has been associated with severe and potentially fatal cases of renal or kidney failure. In May 2006, the FDA required a warning be placed on the product regarding the risk of kidney failure.
Most commonly, patients who have a toxic reaction to OSP suffer acute renal failure, which may lead to chronic and long-term dialysis or death. Those persons who are at the greatest risk are older people, those with decreased intravascular volume or preexisting kidney disease, and those using certain medications such as diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and some nonsteroidal anti-inflammatory drugs (NSAIDs). A kidney biopsy may be helpful in identifying the source of the patient’s kidney failure. If you need additional information about these cases, please contact Ben Locklar in our Mass Tort Section at 800-898-2034.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.